Dual-Linker Antibody-Drug Conjugates for BH3 Synergy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and autoimmune diseases targeting Bcl-2 family proteins, such as Bcl-2, Bcl-xL, and Mcl-1, lack effective disease-modifying agents, particularly in combination therapies, and there is a need for therapeutics that synergize with BH3 mimetics to overcome resistance to anti-cancer treatments and autoimmune disease severity.
Innovation Solution
Development of antibody-drug conjugates (ADCs) linking antibodies or antigen-binding fragments to two antineoplastic compounds, including at least one BH3 mimetic, through a dual linker, allowing for combinations like BH3 mimetics with topoisomerase 1 inhibitors or anti-mitotic drugs, enhancing apoptosis induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapies targeting Bcl-2 family proteins are used, then treatment simplicity is maintained, but therapeutic efficacy and ability to overcome resistance are insufficient
Solution Approach 1:
The patent combines multiple antineoplastic compounds (including BH3 mimetics and other mechanisms) into a single ADC molecule with a dual linker system. This merging allows simultaneous delivery of multiple therapeutic agents that work synergistically to target Bcl-2 family proteins and overcome resistance, while maintaining a single administrable therapy rather than requiring multiple separate drugs.
Solution Approach 2:
The ADC construct functions as a composite therapeutic molecule integrating different pharmacological components (BH3 mimetic payload, linker molecules, and antibody) into a single unified agent. This composite structure enables the simultaneous activation of multiple therapeutic mechanisms against cancer cells expressing Bcl-2 family proteins.
2Reliability
If combination therapies are used to overcome resistance, then therapeutic efficacy improves, but ease of administration and patient compliance deteriorate
Solution Approach 1:
Multiple antineoplastic compounds that would traditionally require separate administration are merged into a single ADC molecule. The dual linker system enables covalent attachment of multiple payloads to one antibody molecule, creating a single administrable therapy that delivers combined therapeutic effects without requiring multiple separate injections or treatments.
3Adaptability or versatility
If multiple antineoplastic compounds are delivered separately, then therapeutic coverage is comprehensive, but treatment time and patient burden increase
Solution Approach 1:
The patent merges multiple antineoplastic compounds into a single ADC molecule with a dual linker system that covalently attaches multiple payloads. This allows comprehensive therapeutic coverage against multiple mechanisms of resistance and diverse cancer cell populations to be achieved in a single administration, eliminating the need for sequential or simultaneous separate treatments.
Solution Approach 2:
Multiple antineoplastic compounds are pre-linked to the antibody molecule during manufacturing, creating a ready-to-administer therapeutic that already contains all necessary therapeutic components. This preliminary assembly of multiple agents into one molecule eliminates the need for patients to receive multiple separate treatments over time.
Data Source
AI summary
Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to at least one BH3 mimetic through a dual linker. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising at least one BH3 mimetic and methods of making the same are also disclosed.